Gestational Diabetes and Pharmacotherapy (GAP)

What Was Tested

In this phase 4 trial, researchers set out to test Insulin (regular human).

It had two arms (groups): one (active comparator) and one (active comparator).

The registry classes the interventions as drug.

More on the Plan

No randomized studies have been performed on how to define failure with diet and exercise and currently, the need to start insulin or oral hypoglycemic agents is at the provider's discretion.

Hypothesis 1.2: Preeclampsia and cesarean birth frequencies will be lower in earlier insulin initiation compared with the active control group.

Hypothesis 1.3: The composite neonatal and maternal outcomes will not differ between racial and ethnic groups within each study group.

Aim 2:Assess the safety of earlier insulin initiation in pregnant patients and their neonates.

Who Took Part

416 planned participants were the target.

It was open to women only aged from 18 years up to 45 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Viable singleton pregnancy. Age \>= 18 years old. Diagnosed with gestational diabetes mellitus. Able to communicate in English.

The full record lists 4 inclusion and 4 exclusion criteria; among the exclusions: pre-gestational diabetes; patients who check blood sugars on average less than 2 times per day after appropriate counseling.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Random assignment meant chance, not the researchers, decided who got Insulin (regular human) and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Insulin (regular human) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2021-05-04 with completion listed for 2026-06-15.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Composite Neonatal Outcome (time frame: The data will be collected up to 6 weeks of life).

It also tracked 2 secondary outcomes, for example Cesarean Delivery Rate and Preeclampsia.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Insulin (regular human) in 416 people.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Insulin (regular human) compound page, all human trials.